---
title: "Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285301847.md"
description: "TD Cowen analyst Daniel Brennan has reiterated a Buy rating on GRAIL Inc, raising the price target to $69. This decision is based on strong first-quarter performance, robust uptake of the Galleri test, and a 50% growth in volume. Upcoming clinical and regulatory catalysts, including data releases at ASCO and positive feedback from oncologists, further support his optimistic outlook on the company's market potential and cash position."
datetime: "2026-05-06T02:45:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285301847.md)
  - [en](https://longbridge.com/en/news/285301847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285301847.md)
---

# Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69

TD Cowen analyst Daniel Brennan reiterated a Buy rating on GRAIL Inc yesterday and set a price target of $69.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Daniel Brennan has given his Buy rating due to a combination of factors, including stronger‑than‑expected first‑quarter performance and robust uptake of the Galleri test. Revenue and Galleri sales modestly surpassed forecasts on the back of roughly 50% volume growth, expanding prescriber adoption, and improving gross margins, supporting confidence in the company’s commercial trajectory and cash position.

Brennan’s constructive stance also reflects upcoming clinical and regulatory catalysts that could further validate Galleri and expand its market opportunity. He highlights extensive data releases at ASCO, encouraging expert feedback on stage‑shift benefits, ongoing dialogue with the FDA, and positive expectations for oncologist receptivity, all of which underpin his upwardly revised $69 price target and support the Buy recommendation.

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead](https://longbridge.com/en/news/286677381.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)